Home > Oncology > WCLC 2018 > Patient-reported outcomes of first-line nivolumab + ipilimumab in high tumour mutational burden advanced non-small-cell lung cancer

Patient-reported outcomes of first-line nivolumab + ipilimumab in high tumour mutational burden advanced non-small-cell lung cancer

Non-squamous non-small-cell lung carcinoma (NSCLC) tumours are tested for driver mutations and rearrangements, typically EGFR, ALK, ROS1, MET, and BRAF. In many centres, it is also common to screen for less frequent but potentially targetable mutations, including RET, ERBB2/HER2, and NTRK fusions [1].

In time, novel immune checkpoint inhibitors (ICIs) will treat growing numbers of driver cell mutations in squamous and non-squamous tumours. Combinations of ICIs alone and with chemotherapy hold promise for prolonging PFS and OS in patients with high PD-L1 expressing tumours. Growing knowledge of the biology of NSCLC is rapidly reshaping treatment advanced disease.

Patient-reported health-related quality of life (HRQoL) outcomes from the CheckMate 227 study [2] suggest rapid and sustained improvements in patients treated with nivolumab + ipilimumab vs chemotherapy.

The phase 3, randomised CheckMate 227 trial enrolled patients with advanced NSCLC and a high tumou...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on